Marathon Petroleum Corp vs Revvity Inc — how do they compare? Marathon Petroleum Corp trades at $455.03 (market cap $130.12B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Marathon Petroleum Corp is far larger — about 7.7× Revvity Inc's market cap, and Marathon Petroleum Corp pays the higher dividend (0.86%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Revvity Inc for 12 Days on average.
| MPC | RVTY | |
|---|---|---|
Market Cap | $130.12B | $16.98B |
Volume | 2,749,647 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $463.34 | $157.36 |
52-Week Low | $162.63 | $82.26 |
Typical Hold Time | 54 Days | 12 Days |
Enterprise Value | $156.64B | $19.30B |
Dividend Yield | 0.86% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $463.34, up 4.77% with strong bullish momentum. The stock shows robust technical strength with consistent earnings beats and favorable valuation metrics including P/E of 16.07 and P/S of 0.9. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions create uncertainty. The company maintains solid profitability with 5.57% net margin and exceptional 47.9% ROE.
MPC presents a compelling investment case with strong fundamentals and analyst support, though near-term risks include regulatory uncertainty and volatile energy markets. With 75.76% analyst buy ratings and $420.30 consensus target, the stock offers growth potential despite trading above target. Investors should weigh strong cash flow generation against exposure to energy policy changes and margin compression risks.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →